Boston Scientific (BSX) to Release Earnings on Wednesday

Boston Scientific (NYSE:BSX) is projected to post its Q1 2026 results before the market opens on Wednesday, April 22nd. Analysts expect the company to announce earnings of $0.7930 per share and revenue of $5.1861 billion for the quarter. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Investors may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, April 22, 2026 at 8:00 AM ET.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.02. The company had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.Boston Scientific’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.70 earnings per share. On average, analysts expect Boston Scientific to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Boston Scientific Price Performance

NYSE BSX opened at $61.00 on Tuesday. The company has a market capitalization of $90.66 billion, a PE ratio of 31.45, a price-to-earnings-growth ratio of 0.99 and a beta of 0.78. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The business’s fifty day moving average is $69.34 and its 200 day moving average is $86.58. Boston Scientific has a fifty-two week low of $60.59 and a fifty-two week high of $109.50.

Insider Activity at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.34% of the stock is owned by insiders.

Hedge Funds Weigh In On Boston Scientific

Several large investors have recently made changes to their positions in BSX. Maverick Capital Ltd. purchased a new position in shares of Boston Scientific in the fourth quarter valued at about $280,735,000. Farallon Capital Management LLC lifted its position in shares of Boston Scientific by 56.7% in the fourth quarter. Farallon Capital Management LLC now owns 7,439,564 shares of the medical equipment provider’s stock valued at $709,362,000 after acquiring an additional 2,693,007 shares in the last quarter. Marshall Wace LLP lifted its position in shares of Boston Scientific by 30.7% in the third quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider’s stock valued at $956,680,000 after acquiring an additional 2,301,383 shares in the last quarter. Morgan Stanley lifted its position in shares of Boston Scientific by 10.8% in the fourth quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock valued at $2,189,289,000 after acquiring an additional 2,246,308 shares in the last quarter. Finally, Credit Agricole S A purchased a new position in shares of Boston Scientific in the third quarter valued at about $204,812,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Piper Sandler reaffirmed an Overweight/positive view on BSX, reflecting continued analyst support around the company’s franchise and WATCHMAN readouts. Here’s What Piper Sandler Thinks About Boston Scientific Corp (BSX) Now
• Neutral Sentiment: Sector and market context remain mixed — long‑term medtech trends (e.g., growth in drug‑eluting stents and focus on high‑growth segments such as PFA) support industry demand but do not remove short‑term execution risk. Drug-Eluting Stents – Global Market Trends, Developments and Investment Opportunities 2026-2034
• Negative Sentiment: Proliferation of securities‑litigation notices and lead‑plaintiff solicitations (multiple law firms — Rosen, Robbins LLP, Glancy Prongay Wolke, Bronstein Gewirtz & Grossman, Faruqi & Faruqi — asking investors to contact them ahead of the May 4 deadline) is creating headline risk and likely weighing on sentiment. BSX FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL
• Negative Sentiment: Truist trimmed its price target (to $90 from $92) while keeping a Buy—small analyst downtick that can encourage sellers ahead of earnings. Truist Cuts PT on Boston Scientific Corporation (BSX) to $90 From $92
• Negative Sentiment: Pre‑earnings de‑risking ahead of BSX’s quarterly report (scheduled April 22) and investor uncertainty about how recent WATCHMAN FLX clinical data will translate into near‑term procedure volume, reimbursement, and competitive positioning have pressured the stock. Boston Scientific (BSX) slips 3.3% as investors stay cautious ahead of upcoming results and after recent trial and legal headlines
• Negative Sentiment: Institutional and insider selling highlighted in market summaries (large fund reductions and notable insider sales) amplify downside pressure and liquidity risk around near‑term news. Quiver Quant BSX Coverage

Analyst Ratings Changes

Several equities analysts recently weighed in on BSX shares. Barclays lowered their target price on Boston Scientific from $136.00 to $124.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 3rd. Truist Financial lowered their target price on Boston Scientific from $92.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, April 15th. UBS Group lowered their target price on Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a research report on Tuesday, March 17th. Weiss Ratings downgraded Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, February 4th. Finally, Canaccord Genuity Group lowered their target price on Boston Scientific from $112.00 to $109.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $102.82.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.